GlassScriptPhysician profile
James Bernhart Hunter
NPI 1982620241
$1,717.91
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,267 · 2020: $244 · 2021: $147 · 2022: $59.28.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $522.54 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.23 | 2019-2020 | |
| Janssen Biotech, INC. | $226.44 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $182.95 | 2019-2020 | |
| Gilead Sciences, INC. | $122.67 | 2019 | |
| Ferring Pharmaceuticals INC. | $112.39 | 2019-2020 | |
| Braintree Laboratories, INC. | $53.88 | 2019 | |
| Ucb, INC. | $41.71 | 2019 | |
| Romark Laboratories, Lc | $39.53 | 2019-2020 | |
| Qol Medical, LLC | $31.52 | 2019 | |
| Enterra Medical, INC. | $25.31 | 2022 | |
| Daiichi Sankyo INC. | $16.17 | 2019 | |
| Dynavax Technologies Corporation | $14.51 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.66 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.09 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $11.36 | 2019 | |
| Merck Sharp & Dohme LLC | $10.95 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.